Comparison of sequencing, restriction fragment length polymorphism (RFLP) and line probe assays for detection of HBV mutants associated with lamivudine therapy: Daryl T Lau, Univ of Texas Medical Branch, Galveston, TX; Angeline Bartholomeusz, Anna Ayres, Victoria Infectious Diseases Reference Lab, North Melbourne Australia; Hongbao Ma, Univ of Texas Medical Branch, Galveston, TX; Jay H Hoofnagle, NIDDK, NIH, Bethesda, MD; Lynn Condreay, Josee Gauthier, GlaxoSmithKline, Research Triangle Park, NC; Geert Maertens, Innogenetics, Known Belgium; Stephen Locarnini, Victoria Infectious Diseases Reference Lab, North Melbourne Australia

Zdroj: In Hepatology 2001 34(4) Part 2:A611-A611
Databáze: ScienceDirect
Externí odkaz: